Compare Aspen Aerogels Inc (ASPN) vs Expensify Inc (EXFY) Price & Performance

Aspen Aerogels (ASPN) trades at $6.13, down 2.54% today, with a bullish technical signal from moving averages despite mixed oscillators. The company shows improving revenue trends with Q2 2026 results beating expectations and strong Q3 guidance of $65-80 million revenue. However, profitability remains challenged with negative net income margins of -62.45% and consecutive quarterly EPS misses. Analyst sentiment is overwhelmingly positive with 82.61% buy ratings.

The outlook balances strong revenue growth potential in thermal barrier markets against persistent profitability challenges. Investment opportunity lies in the expanding EV thermal barrier business and European market growth, while risks include sustained negative cash flow and competitive pressures in evolving battery technologies.

Expensify (EXFY) trades at $2.4, down 2.83% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $33.9 million, beating EPS estimates, and raised free cash flow guidance. However, it remains unprofitable on a net income basis, with a negative margin of -11.31% and a high P/E ratio of 258.82, indicating a premium valuation despite losses. Recent news highlights expansion into Europe and AI product enhancements.

The outlook is mixed; operational improvements and AI-driven growth offer upside, but persistent losses and high valuation pose risks. Analyst sentiment is balanced with a 44% buy rating. Investors should weigh the potential for margin expansion against the challenge of achieving sustained profitability.